CVS Q1 revenue $100.4B (+6.2% YoY); raises FY26 EPS guidance to $7.30-7.50

CVS HEALTH Corp

2026-Q1 EPS reported $2.30 revenue$100,426,000,000

GAAP diluted EPS $2.30 vs $1.41 YoY; Adjusted EPS $2.57 vs $2.25 YoY.
Health Care Benefits MBR improved to 84.6% (down 270 bps); adjusted op income up 52.6% to $3.04B.
Health Services segment revenue $48.2B (+11.0%) but adj op income -7.1% on client price improvements.
Pharmacy & Consumer Wellness adj op income -8.8% due to reimbursement pressure and seasonal illness decline.
FY26 guidance raised: GAAP EPS $6.24-6.44 (from $5.94-6.14); cash from ops at least $9.5B (from $9.0B).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CVS HEALTH Corp reported the three months ended March 31, 2026 results: revenue $100.4 billion, net income $2,957, EPS $2.30. Guidance raised.

Period: the three months ended March 31, 2026
Revenue: $100.4 billion
Net income: $2,957
EPS: $2.30
Guidance: raised
Result: reported results

Exact text from the filing

CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE • First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year • First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57

View on SEC.gov

Browse all earnings releases →

CVS HEALTH Corp filing history →

Source: SEC EDGAR

accession 0000064803-26-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.